Published in Hepatitis Weekly, January 29th, 2001
In a study comparing C57BL/6J (B6) mice and non-obese diabetic (NOD) mice, "NOD mice were at least 100-fold more resistant to recombinant human TNF-alpha and D-galactosamine treatment than B6 mice," reported F.R. Bahjat and colleagues at the University of Florida. Other experiments had already demonstrated reduced apoptotic activity,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.